Interpretation of Mavacamten’s medical insurance reimbursement policy

Mavacamten (mavacamten) is an innovative drug that has attracted much attention in the cardiovascular field in recent years. Its core value lies in its specific mechanism for obstructive hypertrophic cardiomyopathy (oHCM), making it one of the few drugs in the world with targeted treatment options. With the Chinese original drug Camzyos (Maifantuo) approved for marketing in 2024, the medical insurance coverage policy has also been implemented simultaneously, becoming a focus of concern for patients. Domestically, Mavakatai has been included in the national medical insurance catalog and has been gradually implemented for reimbursement in various provinces.

Common packaging specifications of this drug include 2.5mg, 5mg, 10mg, 15mg, etc., all sold in the form of 14 tablets * 2 tablets. Patients can choose according to the dynamic dose adjustment evaluated by the doctor. The scope of medical insurance payment is limited to adult oHCM patients in New York Heart Association (NYHA) class II–III, which is highly consistent with the recommended population in overseas guidelines. The actual reimbursement ratio of medical insurance will vary depending on regional policies. First-tier cities generally provide higher reimbursement ratios, which can effectively reduce long-term medication costs for patients. Since Mavaceta is a drug that requires strict monitoring of cardiac function, the national medical insurance adopts a management method of "limited user population + dynamic evaluation" when including it, which not only ensures that patients can afford it, but also avoids unnecessary abuse. This management model has become increasingly popular in innovative drug and medical insurance negotiations in recent years and has high sustainability.

In addition to outpatient special disease, hospitalization reimbursement and other channels, some hospitals have also added cardiomyopathy specialist outpatient clinics to provide patients with more standardized medication and follow-up procedures and improve the convenience of medical insurance reimbursement. Overall, the implementation of Mavakatai medical insurance coverage has significantly improved the accessibility of oHCM patients, and also promoted the domestic cardiomyopathy treatment field to align with international standards.

Reference materials:https://bnf.nice.org.uk/drugs/mavacamten/